glp-1 heart failure reduced ejection fraction Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit

Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials

28.85

★★★★☆4.8 (126)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

28.84

★★★★★4.9 (98)

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms in: Journal of Endocrinology Volume 263 Issue 1 (2024)

20.86

★★★★★5.0 (157)

3. Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD

27.89

★★★★★4.7 (84)

Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure

22.02

★★★★★4.9 (203)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) | Cardiovascular Diabetology

21.48

★★★★★5.0 (176)

Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: A propensity score matching study

28.62

★★★★★4.8 (132)